北京康辰药业股份有限公司2025年年度业绩预告

Core Viewpoint - Beijing Kangchen Pharmaceutical Co., Ltd. anticipates a significant increase in net profit for the year 2025, projecting a rise of 243% to 315% compared to the previous year [2][4]. Group 1: Performance Forecast - The company expects to achieve a net profit attributable to shareholders of the parent company between 145 million yuan and 175 million yuan for the year 2025, an increase of 102.78 million yuan to 132.78 million yuan compared to the previous year [2][4]. - The forecasted net profit, excluding non-recurring gains and losses, is expected to be between 140 million yuan and 170 million yuan, representing an increase of 108.92 million yuan to 138.92 million yuan year-on-year [2][4]. Group 2: Previous Year’s Performance - In the previous year (2024), the total profit was 38.86 million yuan, with a net profit attributable to shareholders of the parent company of 42.22 million yuan, and a net profit excluding non-recurring gains and losses of 31.08 million yuan [6]. Group 3: Reasons for Performance Increase - The substantial increase in profit is attributed to the absence of goodwill impairment losses, which were incurred in the previous year due to the acquisition of the former Tai Ling Pharmaceutical International Co., Ltd. [8].